Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of PBCLN-003 in Healthy Adults
NCT05516225Phase 1Completed
- Sponsor
- Prolacta Bioscience
- Start
- Sep 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PBCLN-003 in Clostridium difficile infection (CDI) (4 arms), sponsored by Prolacta Bioscience. Primary endpoint: Number of Adverse Events at 28 days. Started Sep 2016; status: completed.
02
Drugs
PBCLN-003
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT05516225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05516225.